척수성 근위축증 시장 : 유형별, 치료법별, 연령층별, 투여 경로별, 유통 채널별, 지역별

Spinal Muscular Atrophy Market, by Type, by Treatment, by Age Group, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2025 - 2032

US $ 4,500 ￦ 6,713,000

Unprintable PDF & Excel (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 7,000 ￦ 10,442,000

PDF & Excel (Multi User License - Up to 7 Users)

PDF & Excel 보고서를 동일 기업 최대 7명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능하며, 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

US $ 10,000 ￦ 14,918,000

PDF & Excel (Corporate User License)

PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 척수성 근위축증 시장은 2025년 20억 1,890만 달러로 추정되며, 2032년에는 48억 9,890만 달러에 달할 것으로 예상되며, 2025년부터 2032년까지 연평균 13.5%의 CAGR로 성장할 것으로 예상됩니다.

보고서 범위		보고서 상세
기준 연도	2024년	2025년 시장 규모	20억 1,890만 달러
실적 데이터	2020년부터 2024년까지	예측 기간	2025년부터 2032년까지
예측 기간 : 2025-2032년 CAGR	13.50	2032년 가치 예측	48억 9,890만 달러

척수성 근위축증(SMA)은 말초신경계, 중추신경계, 의지근 운동(골격근)에 영향을 미치는 유전병으로, 주로 신경세포의 자극을 받지 않는 근육에 영향을 미치기 때문에 근육성 질환입니다. 위축은 의학용어로 근육이 수축하는 것을 의미하며, 신경세포의 자극을 받지 못하는 근육이 위축되는 것을 말하며, SMA는 운동 뉴런 질환으로 척수의 운동 뉴런이라는 신경세포가 소실되는 질환입니다. SMA 환자는 생존운동뉴런1(SMN1) 유전자의 이상(돌연변이) 또는 결손을 2개씩 물려받게 되며, 주로 영아나 소아에게 발병하지만 성인에게도 발병할 수 있습니다.

시장 역학

시장의 주요 업체들의 제품 출시가 증가함에 따라 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 2021년 8월, 일본에서 사업을 전개하는 제약회사 중외제약은 척수성 근위축증(SMA) 치료제로 에브리스디 건조시럽 60mg(일반명: 리스디플럼)을 출시했다고 발표했습니다.

또한, 주요 기업들의 제휴 및 공동 연구와 같은 무기 전략의 채택이 증가하고 있으며, 이는 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 2021년 3월, 세계 SMA 연구의 주요 자금 제공자인 척수성 근위축증 재단과 미국 제약회사 PTC Therapeutics, Inc.는 SMA 및 기타 신경근육 질환에 대한 과학적 연구를 더욱 발전시키기 위해 새로운 치료법 및 재생 의학 개발에 초점을 맞춘 새로운 제휴를 체결했습니다. 를 체결했습니다.

본 조사의 주요 특징

• 세계의 척수성 근위축증 시장을 상세히 분석하여 2024년을 기준 연도로 하여 예측 기간(2025-2032년)의 시장 규모와 연평균 성장률(CAGR)을 조사 분석하여 전해드립니다.
• 또한, 다양한 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
• 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 주요 인사이트를 제공합니다.
• 세계 척수성 근위축증 시장의 주요 기업들을 회사 소개, 제품 포트폴리오, 주요 특징, 주요 성과, 전략 등의 매개 변수를 기반으로 프로파일링합니다.
• 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
• 척수성 근위축증 세계 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가1 등 다양한 이해관계자를 대상으로 합니다.
• 이해관계자들은 세계 척수성 근위축증 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.

목차

제1장 조사 목적과 가정

• 조사 목적
• 가정
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 시장 기회
• 영향 분석
• 시장 동향
• 인수와 제휴 시나리오
• 기술의 진보
• 규제 시나리오
• PEST 분석
• 제품 발매

제4장 세계의 척수성 근위축증 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향

• 전체적인 영향
• 정부 이니셔티브
• COVID-19의 시장에 대한 영향

제5장 척수성 근위축증 세계 시장, 유형별, 2020-2032년

• 유형 I
• 유형 II
• 유형 III
• 유형 IV

제6장 세계의 척수성 근위축증 시장, 치료별, 2020-2032년

• 유전자 치료
• 질환 조절약

제7장 세계의 척수성 근위축증 시장, 연령별, 2020-2032년

• 유아
• 성인

제8장 세계의 척수성 근위축증 시장, 투여 경로별, 2020-2032년

• 경구
• 주사

제9장 세계의 척수성 근위축증 시장, 유통 채널별, 2020-2032년

• 병원 약국
• 소매 약국
• 온라인 약국

제10장 세계의 척수성 근위축증 시장, 지역별, 2020-2032년

• 북미
• 라틴아메리카
• 유럽
• 아시아태평양
• 중동
• 아프리카

제11장 경쟁 구도

• Biogen
• CYTOKINETICS
• F. Hoffmann-La Roche Ltd
• Genentech, Inc.
• PTC Therapeutics, Inc.
• Novartis AG
• Ionis Pharmaceuticals
• Chugai Pharmaceutical Co., Ltd.
• NMD PHARMA A/S
• Astellas Pharma Inc.

제12장 애널리스트의 추천사항

• 기회
• 애널리스트의 견해
• Coherent Opportunity Map

제13장 섹션

• 참고문헌
• 조사 방법

ksm

영문 목차

영문목차

Global Spinal Muscular Atrophy Market is estimated to be valued at USD 2,018.9 Mn in 2025 and is expected to reach USD 4,898.9 Mn by 2032, growing at a compound annual growth rate (CAGR) of 13.5% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 2,018.9 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	13.50%	2032 Value Projection:	USD 4,898.9 Mn

Spinal muscular atrophy (SMA) is a genetic disease that affects the peripheral nervous system, central nervous system, and voluntary muscle movement (skeletal muscle). SMA is muscular since it primarily affects muscles, which do not receive impulses from the nerve cells. Atrophy is the medical term for shrinking, which is what muscles do when they are not stimulated by nerve cells. SMA is a motor neuron disease that includes the loss of nerve cells termed motor neurons in the spinal cord. It mostly affects infants and children but can also develop in adults. An individual with SMA inherits two copies of a faulty (mutated) or missing survival motor neuron 1 (SMN1) gene.

Market Dynamics

The increasing product launches by the key players in the market are expected to drive the market growth over the forecast period. For instance, in August 2021, Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan, announced that it had launched Evrysdi Dry Syrup 60 mg (generic name: risdiplam) for the treatment of spinal muscular atrophy (SMA).

Moreover, the increasing adoption of inorganic strategies such as partnerships and collaborations by the key players is expected to drive the market growth over the forecast period. For instance, in March 2021, the Spinal Muscular Atrophy Foundation, the leading funder of SMA research worldwide, and PTC Therapeutics, Inc., a U.S. based pharmaceutical company, entered into a new collaboration focused on developing new treatments and regenerative medicine to further advance scientific research in SMA and other neuromuscular disorders.

Key features of the study:

• This report provides in-depth analysis of the global spinal muscular atrophy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global spinal muscular atrophy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Biogen, CYTOKINETICS, Hoffmann-La Roche Ltd, Genentech, Inc., PTC Therapeutics, Inc., Novartis AG, Ionis Pharmaceuticals, Chugai Pharmaceutical Co., Ltd., NMD PHARMA A/S, and Astellas Pharma Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global spinal muscular atrophy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global spinal muscular atrophy market

Detailed Segmentation:

• Global Spinal Muscular Atrophy Market, By Type:
  • Type I
  • Type II
  • Type III
  • Type IV
• Global Spinal Muscular Atrophy Market, By Treatment:
  • Gene Therapy
  • Disease-modifying drugs
• Global Spinal Muscular Atrophy Market, By Age Group:
  • Infant
  • Adult
• Global Spinal Muscular Atrophy Market, By Route of Administration:
  • Oral
  • Injectables
• Global Spinal Muscular Atrophy Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Spinal Muscular Atrophy Market, By Region:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles
  • Biogen
  • CYTOKINETICS
  • Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • PTC Therapeutics, Inc.
  • Novartis AG
  • Ionis Pharmaceuticals
  • Chugai Pharmaceutical Co., Ltd.
  • NMD PHARMA A/S
  • Astellas Pharma Inc

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Treatment
  • Market Snapshot, By Age
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Acquisitions and Partnerships Scenario
• Technological Advancements
• Regulatory Scenario
• PEST Analysis
• Product Launches

4. Global Spinal Muscular Atrophy Market- Impact of Coronavirus (Covid-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the market

5. Global Spinal Muscular Atrophy Market, By Type, 2020 - 2032, (US$ Million)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Type I
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Type II
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Type III
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Type IV
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

6. Global Spinal Muscular Atrophy Market, By Treatment, 2020 - 2032, (US$ Million)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Gene Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Disease-modifying drugs
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

7. Global Spinal Muscular Atrophy Market, By Age, 2020 - 2032, (US$ Million)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Infant
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Adult
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

8. Global Spinal Muscular Atrophy Market, By Route of Administration, 2020 - 2032, (US$ Million)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Injectables
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

9. Global Spinal Muscular Atrophy Market, By Distribution Channel, 2020 - 2032, (US$ Million)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

10. Global Spinal Muscular Atrophy Market, By Region, 2020 - 2032, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Regions, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Age, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Age, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Age, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • UK
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Age, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Age, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Age, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa

11. Competitive Landscape

• Biogen
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• CYTOKINETICS
• F. Hoffmann-La Roche Ltd
• Genentech, Inc.
• PTC Therapeutics, Inc.
• Novartis AG
• Ionis Pharmaceuticals
• Chugai Pharmaceutical Co., Ltd.
• NMD PHARMA A/S
• Astellas Pharma Inc.

12. Analyst Recommendation

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

13. Section

• References
• Research Methodology
• About Us and Sales Contact

관련자료